Amarin shares will bounce back on 2019 catalysts, says Jefferies

After hosting meetings with management, Jefferies analyst Michael Yee says Amarin represents one of the few “de-risked” standalone blockbuster drugs in the smid-cap Biotech space. Following the stock’s pullback from of $23 to $15, Amarin will “bounce and go back up,” predicts the analyst. He sees 2019 catalysts from “scripts and sales ramp to FDA approval.” Further, a potential takeout is a “wildcard,” writes Yee in a note titled “The Big Fish In A Big Pond? Update from Mgmt Meetings…” The analyst keeps a Buy rating on Amarin with a $30 price target.

https://thefly.com/landingPageNews.php?id=2839867